The KIFC3 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 lung adenocarcinoma cell line. These cells harbor a targeted disruption of the KIFC3 gene, which encodes a minus-end-directed kinesin motor protein. The polyclonal format provides a heterogeneous pool of edited cells, enabling the study of KIFC3 loss-of-function without the clonal selection biases inherent in monoclonal lines. This model is a valuable tool for investigating the roles of KIFC3 in mitotic progression, Golgi organization, and intracellular transport, particularly in the context of EGFR-mutant NSCLC.
The parental NCI-H1975 cell line was established from a female nonsmoker with lung adenocarcinoma and carries activating EGFR L858R and T790M mutations. These genetic alterations confer sensitivity to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs) and are clinically relevant for studying acquired resistance mechanisms. NCI-H1975 cells exhibit an epithelial morphology and serve as a well-characterized model for EGFR-driven NSCLC, making them suitable for exploring the interplay between oncogenic signaling and cytoskeletal dynamics.
KIFC3 functions as a minus-end-directed microtubule motor protein that mediates retrograde transport of Golgi-derived vesicles and contributes to mitotic spindle pole organization. Its activity is regulated by upstream factors including the transcription factor FOXM1, E2F family members, and the cyclin-dependent kinase CDK1. KIFC3 interacts with 14-3-3 beta and zeta adaptor proteins, dynein, and microtubules to execute its cellular roles. Downstream, KIFC3 ensures proper Golgi complex positioning and chromosome alignment during mitosis, in concert with tubulin, spindle assembly checkpoint components BUB1 and MAD2, and Golgi matrix proteins GM130 and giantin. The CDK1/cyclin B complex further coordinates these mitotic events. Depletion of KIFC3 disrupts Golgi structure and chromosome alignment, leading to mitotic defects and potential aneuploidy, thereby contributing to cancer progression.
In the NCI-H1975 background, KIFC3 knockout may exacerbate mitotic abnormalities driven by EGFR oncogenic signaling. The EGFR L858R/T790M mutations sustain proliferative signals that could synergize with KIFC3 loss-induced spindle assembly defects, promoting chromosomal instability and aneuploidy. This model enables dissection of how KIFC3-dependent mitotic fidelity influences the survival and drug response of EGFR-mutant NSCLC cells. Additionally, the interplay between KIFC3-mediated Golgi organization and EGFR trafficking or glycosylation may be probed, offering insights into novel therapeutic vulnerabilities.
Researchers can employ these polyclonal knockout cells in a variety of assays to assess KIFC3 function. Western blotting confirms KIFC3 protein knockdown, while immunofluorescence microscopy using antibodies against GM130 and ??-tubulin visualizes Golgi morphology and mitotic spindle architecture. Flow cytometry facilitates cell cycle profiling and aneuploidy assessment. Functional assays such as colony formation and apoptosis assays evaluate long-term proliferation and survival. Drug sensitivity testing with paclitaxel or EGFR inhibitors (e.g., osimertinib) can reveal synthetic lethal interactions or resistance mechanisms. The cells are suitable for target validation studies and for investigating the cytoskeletal determinants of NSCLC progression. For further information or to request a quote, please contact Ascent Research.
